Literature DB >> 11119715

Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells.

C Faveeuw1, S Fougeray, V Angeli, J Fontaine, G Chinetti, P Gosset, P Delerive, C Maliszewski, M Capron, B Staels, M Moser, F Trottein.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily. They are divided into three subtypes (alpha, beta or delta, and gamma) and are involved in lipid and glucose homeostasis and in the control of inflammation. In this study, we analyzed the expression of PPARs in murine dendritic cells (DCs), the most potent antigen presenting cells. We find that immature as well as mature spleen-derived DCs express PPARgamma, but not PPARalpha, mRNA and protein. We also show that the PPARgamma activator rosiglitazone does not interfere with the maturation of DCs in vitro nor modifies their ability to activate naive T lymphocytes in vivo. Finally, we present evidence that PPARgamma activators down-modulate the CD40-induced secretion of interleukin-12, a potent Th1-driving factor. These data suggest a possible role for PPARgamma in the regulation of immune responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11119715     DOI: 10.1016/s0014-5793(00)02319-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  41 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

2.  Virus-induced differential expression of nuclear receptors and coregulators in dendritic cells: implication to interferon production.

Authors:  Sinnie Sin Man Ng; Tsung-Hsien Chang; Prafullakumar Tailor; Keiko Ozato; Tomoshige Kino
Journal:  FEBS Lett       Date:  2011-04-07       Impact factor: 4.124

Review 3.  Energy metabolic pathways control the fate and function of myeloid immune cells.

Authors:  Amir A Al-Khami; Paulo C Rodriguez; Augusto C Ochoa
Journal:  J Leukoc Biol       Date:  2017-05-17       Impact factor: 4.962

4.  Effects of rosiglitazone on proliferation and differentiation of duck preadipocytes.

Authors:  Fang Ding; Jiamin Qiu; Qingqing Li; Jiwei Hu; Chenling Song; Chunchun Han; Hua He; Jiwen Wang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-10-20       Impact factor: 2.416

Review 5.  Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.

Authors:  Wei Cai; Tuo Yang; Huan Liu; Lijuan Han; Kai Zhang; Xiaoming Hu; Xuejing Zhang; Ke-Jie Yin; Yanqin Gao; Michael V L Bennett; Rehana K Leak; Jun Chen
Journal:  Prog Neurobiol       Date:  2017-10-12       Impact factor: 11.685

Review 6.  Endothelial PPARγ Is Crucial for Averting Age-Related Vascular Dysfunction by Stalling Oxidative Stress and ROCK.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Md Jakaria; Abdullah Al Mamun; Kamal Niaz; Md Shah Amran; George E Barreto; Ghulam Md Ashraf
Journal:  Neurotox Res       Date:  2019-05-04       Impact factor: 3.911

7.  Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects.

Authors:  Renata Bocciardi; Roberto Ravazzolo
Journal:  PPAR Res       Date:  2010-06-16       Impact factor: 4.964

8.  Invariant NKT Cell Activation Induces Late Preterm Birth That Is Attenuated by Rosiglitazone.

Authors:  Derek St Louis; Roberto Romero; Olesya Plazyo; Marcia Arenas-Hernandez; Bogdan Panaitescu; Yi Xu; Tatjana Milovic; Zhonghui Xu; Gaurav Bhatti; Qing-Sheng Mi; Sascha Drewlo; Adi L Tarca; Sonia S Hassan; Nardhy Gomez-Lopez
Journal:  J Immunol       Date:  2016-01-06       Impact factor: 5.422

9.  Peroxisome proliferator-activated receptor γ B cell-specific-deficient mice have an impaired antibody response.

Authors:  Sesquile Ramon; Simona Bancos; Thomas H Thatcher; Thomas I Murant; Safiehkhatoon Moshkani; Julie M Sahler; Andrea Bottaro; Patricia J Sime; Richard P Phipps
Journal:  J Immunol       Date:  2012-10-05       Impact factor: 5.422

10.  Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.

Authors:  B M Brooks-Worrell; J P Palmer
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.